| Publisher’s Note: FierceBiotech will not publish on Thursday or Friday this week due to the holiday. Have a happy and safe Thanksgiving, and we’ll be back in your inbox on Monday, Nov. 26. Today's Rundown CEO of MHRA set to leave agency in wake of Brexit Idorsia sheds surplus DMD therapy to Santhera Biogen tasks HitGen with discovering neurological leads [Sponsored] Mining Real-World Data With Cutting-Edge Analytical Tools Boston Scientific makes $4.2B offer to buy BTG and build out its oncology, vascular franchises Biopharma UCB and Verint Systems launch new Parkinson’s patient app dubbed ‘April’ Featured Story | | | Wednesday, November 21, 2018 The CEO of the U.K. drug regulator is set to leave the agency in 10 months. Ian Hudson’s decision means the agency faces the prospect of changing leaders while dealing with the fallout from Brexit. |
|
|
| This week's sponsor is FierceBiotech. | | | |
Top Stories Wednesday, November 21, 2018 Santhera has agreed to purchase a sublicense to Duchenne muscular dystrophy (DMD) drug vamorolone, originally developed by ReveraGen, from fellow Swiss biotech and Actelion spinout Idorsia. Wednesday, November 21, 2018 Biogen has teamed up with HitGen. The alliance tasks HitGen with applying its DNA-encoded libraries to targets of interest to Biogen to generate novel leads for the big biotech. Wednesday, November 14, 2018 In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In those days, there were no scientific tools to guide prospectors in their search. Sites of previous finds were the starting point for what became, for many, a shattered dream. Tuesday, November 20, 2018 Boston Scientific has reached a deal to absorb BTG for $4.2 billion in cash, acquiring a pipeline that could transform its oncology franchise from one primarily offering delivery tools into a $500 million interventional cancer therapy business. Tuesday, November 20, 2018 Belgium biopharma UCB has partnered with Verint Systems to launch a new app for Parkinson’s patients that offers support and adherence. Enrollment Showcase | | | Sponsored by: Biotech Primer BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today! |
|
|
Resources Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Patheon, part of Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Catalent In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to a patient’s medicine cabinet. The average cost to research and develop a successful drug is approximately $2.6 billion. Sponsored by: Catalent Today’s scientists are under significant time pressure to accelerate their compound from discovery to the clinic. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development. Sponsored by: Catalent What is the fastest way to success? It is critical that drug developers execute several elements related to planning, investment, and understanding of the risks, risk tolerance, and pitfalls inherent in the drug development program. Sponsored by: Forte Research Systems Discover what over 800 of your peers think about technology's impact on clinical trial operations. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Compliance Training for Professionals working in APAC region March 4-7, 2019 | Singapore FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2019 January 8, 2019 | The Fairmont Hotel | San Francisco, CA BioBasics: Biotech For The Non-Scientist December 5-6, 2018 | Boston, MA Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami Molecular Medicine Tri-Conference March 10-15, 2019 | San Francisco, CA | 